



2016 Annual General Meeting presentation

For Immediate Release

November 28, 2016

Sydney, Australia – Simavita Limited (“Simavita” or the “Company”) (ASX: SVA) is pleased to release the attached slide show presentation which will be delivered by its Chairman, Mr Michael Spooner, at the Company’s 2016 Annual General Meeting to be held at 11.00 am this morning at the offices of Simavita Limited, L13, 54 Miller Street, North Sydney NSW 2060.

For further information, please view our website (www.simavita.com) or contact:

Ms Peta Jurd
Chief Commercial Officer

E: pjurd@simavita.com
T: +61 421 466 653
W: Investor Centre: [Click here](#)

About Simavita

Simavita is focused upon the rapid delivery of smart, wearable and disposable sensors for the health care industry. With the support of our shareholders, customers and employees, Simavita is focused upon the business at hand; creating a commercially successful and growing corporation.

To date we have developed and are actively selling automated sensors and systems for the assessment and management of incontinence. Incontinence and the management of incontinence is a major and rapidly growing challenge. The annual cost to the global economy is in the billions of dollars and rising. It is an enormous cost that includes both incontinence materials as well as the significant time spent by carers in helping people suffering from incontinence. Most significantly, it impacts a growing community of seniors as well as people of any age who may be affected by disability and illness.

Simavita operates directly in Australia, Europe and North America where we see significant and growing demand for product that delivers real cost benefit to the health care industry and particularly for people in need.

Forward-Looking Information

This document may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita

has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.



RISING TO THE OPPORTUNITY

Annual General Meeting

28 November, 2016



FORWARD LOOKING STATEMENTS

This presentation may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct. In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology.

By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements.

Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.



BACKGROUND

A COMPANY & MANAGEMENT THAT HAS TRANSITIONED

- Shareholder supported financing and restructuring finalised 27 April 2016
- New Board and Executive Management
- Immediate refocus on delivering incontinence assessment product which meets larger market need
 - **assess**PLUS– Cheaper, Simpler, Incontinence Assessment
 - “Peel & Apply Sensors” – Reduced pricing, higher margins
- A commitment to long term market needs with new innovative product
- 40% reduction in monthly cash burn
- A focus on increased sales performance, breakeven and profit

SHORT TERM OBJECTIVES HAVE BEEN MET

- Significant reduction in monthly cash outflows
- Increased revenue 41% YTD compared to prior corresponding period
- New product delivered in 5 months & under budget - **assess**PLUS
- Development of 'Peel and Apply Sensors' advanced
- Entered new markets of home care & disability care
- De-listed from TSX-V with savings of ~ \$100k per annum forecast
- New ANZ Sales Director appointed resulting in increased pipeline
- Additional geographies entered; The Netherlands commenced with Norway, Sweden & Spain to follow next quarter
- Executive functioning effectively

TARGET MARKETS




WEARABLE TECHNOLOGIES FOR INCONTINENCE DIAGNOSTICS & ASSESSMENT IN EXPANDED MARKETS:

Current markets	New markets
Aged / long term care	Community / home care
Rehabilitation / Skilled nursing facilities	Disability care
Hospital	
Hospice	

EXPANDED MARKETS PROVIDE SIGNIFICANTLY INCREASED OPPORTUNITY:

Addressable market for incontinence pad user - Australia



HOME CARE BUSINESS MODEL

- Growing trend to care for elderly at home
- Australia 858,500 receiving home care support
- US 4.7m people receive services from home health agencies + 273k people attend an adult day service centre
- European home care – UK 800k, NL 350k, Spain 534k, Denmark 140k, Sweden 207k, Germany 1.4m
- Dementia & incontinence key drivers for residential care
- Simavita → Home care provider → Consumer
- Home care provider purchases the hardware kit & assessment (pads & sensors)
- Home care provider sells incontinence assessment to consumer & makes a margin
- Value added service to existing customer base



THE OPPORTUNITY IN DISABILITY CARE

- NDIS - 3 year phased take up of 460,000 participants
- Annual incontinence pad spend of \$230 million
- Estimated 60,000 – 70,000 participants using pads

CASE STUDY

- 25yo female participant in supported housing requiring full assistance for personal care needs
- Although ambulant she is often reluctant to undertake activities
- Participant has no language skills so relies on carer to assessPLUS™ her needs regarding toileting and pad change times.

ASSESSMENT OUTCOMES

- New toileting times recommended
- Significant reduction in night pad capacity
- Annual pad cost savings of \$722
- Significant dehydration issue identified. Hydration plan implemented & participant now engaging in daily exercise activity

TARGET GEOGRAPHIES



TARGET GEOGRAPHIES

CURRENT COUNTRIES	COMMENCING SALES Q3 FY17	MARKET UNDER DEVELOPMENT
Australia	Sweden	Germany
United States	Spain	England
Canada	Norway	New Zealand
Denmark		
The Netherlands		

A FOCUSED SALES STRATEGY VARIES BY TERRITORY

- PAYERS
 - ✓ Government
 - ✓ Insurers
 - ✓ Self funded
- MANUFACTURERS
- PARTNERS
- OPERATORS
- MAJOR SERVICE PROVIDERS
- DIRECT SALES
- EDUCATORS



NEW EASY TO USE SOLUTION



WORLD'S FIRST INTEGRATED & INSTRUMENTED INCONTINENCE ASSESSMENT

SIM[®] Cycle



Incontinence Management made easy


assessPLUS - Clip and Go

Smart Incontinence Management solution (SIM™).
Collecting data and creating evidence based care plans has never been easier or faster!




WHY USE assessPLUS

- **Optimise staff time** spent performing unnecessary toileting and changing of continence products
- **Reduce continence product capacity** - lower operating costs
- **Evidence based care plan** - automated to reduce time and takes out the guesswork
- **Reduce the risk** of falls, UTI's, and skin breakdown associated with continence management



TECHNOLOGY WHICH DELIVERS


- Real “quality of life” improvements
- Care plans & regulatory compliance
- Carer efficiencies
- Cost savings
 - Incontinence pads
 - Carer time
- Falls prevention
- Dehydration data
- Skin care improvement
- Return to continence for some



OUR TECHNOLOGY VISION



TECHNOLGY, INNOVATION, SENSORS



OPENING NEW AND LARGER OPPORTUNITIES


Full Assessment



assessPLUS
Assessment Made Simple



TECHNOLOGY DEVELOPMENT DRIVEN BY DEMAND

Applications	Industry Positioning
Alert Sensor	Aged & Disability
Smart Wearable Sensors	Home Care
GPS Application	Home Care
Falls Application	Home Care
Temperature	Home Care
Pulse/Ox	Home Care
TOTAL	

THE DIFFERENCE LIES IN OUR IP & PEOPLE



A comprehensive and well documented Intellectual Property Portfolio - a major investment

- 12 patent families with significant independent claims
- 46 international granted patents + 35 filed & in progress
- High value patent fields: incontinence management methods across ages, clinical applications, algorithms, software + manufacturing methods

Strong IP

- Wearable Sensors
- Algorithms
- Incontinence management software + methods
- Proprietary incontinence database
- Interface



OUR MANAGEMENT TEAM

- **Mr Michael Spooner, Chairman** – Highly experienced CEO and director, listed international biotechnology companies. Ex Partner Global Consulting Firm.
- **Dr Gary W Pace, Director** – Over 40 years experience in the field as both an executive and non executive director of biotech listed companies in the US, Europe and Australia.
- **Mr Peter Curran, Head of R&D** - The driving force behind Simavita technology platform. A leader with vision.
- **Ms Peta Jurd, Chief Commercial Officer** – Over 20 years experience in health care, management and sales.
- **Mr Chris Southerland, Senior VP Sales North America** – Over 20 years experience in sales to aged care.
- **Mr Wessel Van Dijk, Senior Vice President Europe** – Over 20 years experience in sales to aged care.


SUMMARY



MILESTONES ACHIEVED 2016

- ✓ Board and management restructure
- ✓ ~ 40% reduction in monthly cash spend
- ✓ Delisted from TSX-V (Toronto Ventures Exchange)
- ✓ Delivered assessPLUS™ on time – roll out commenced
- ✓ Increase in sales YOY
- ✓ Approved as NDIS provider in Australia
- ✓ New distributors appointed in all regions
- ✓ Achieved a number of land mark transactions particularly in Australia and Europe.

BREAK EVEN THROUGH TO PROFITABILITY



CONCLUSION

Simavita, with your support, is strongly focused on the business at hand; creating a commercially successful and growing corporation in the field of incontinence and incontinence management.

We have completed the first major step in the restructuring of its activities and our commitment is to continue to rapidly evolve as we strive toward substantial increases in sales, enhanced by the development of new product and the appointment of new distributors.

QUESTIONS